



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**November 6, 2012 6:00 – 8:30 p.m.**

**\*\* PLEASE NOTE RESCHEDULED DATE \*\***

**PLEASE NOTE NEW START TIMES – PUBLIC SESSION STARTS AT 6:30 PM**

- 1. Executive Session** **6:00 - 6:30**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
  
- 2. Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**  
(Public Comment Prior to Board Action)
  
- 3. DVHA Pharmacy Administration Updates** **6:35 - 6:45**
  - Updates
  
- 4. Medical Director Update** **6:45 - 6:50**
  - Clinical Programs Update
  - Prescriber Comments
  
- 5. Follow-up Items from Previous Meetings** **6:50 - 7:10**
  - Atypical Antipsychotics – Pediatric Use
  - Antipsychotics in Children < 6 years old
  
- 6. RetroDUR/DUR** **7:10 – 7:30**
  - 90 Day Mandatory Fill Select Maintenance Medications
  - Suboxone<sup>®</sup>/Buprenorphine (also tablet market withdrawal)
  - Hepatitis C Protease Inhibitors
  
- 7. Clinical Update: Drug Reviews** **7:30 – 7:45**  
(Public comment prior to Board action)  
**Full New Drug Reviews**
  - Intermezzo<sup>®</sup> (zolpidem tartrate) Sublingual Tablet
  - Potiga<sup>®</sup> (ezogabine) Oral Tablet
  
- 8. Therapeutic Drug Classes – Periodic Review** **7:45 – 8:00**  
(Public comment prior to Board action)  
**Class review documents available on DVHA web site 11/06/2012 @ 12 Noon**
  - Inhaled Corticosteroid and Long-Acting  $\beta$ 2-Agonist Combination Products
  - Platelet Inhibitors
  - Topical Androgens (testosterone)

- 9. New Managed Therapeutic Drug Classes** **8:00 – 8:10**  
(Public comment prior to Board action)
- Miscellaneous: Makena<sup>®</sup> (also discussion of compounding pharmacies)
- 10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:10 – 8:20**  
(Public comment prior to Board action)
- Incretin Mimetics
  - Short Acting  $\beta$ 2-Agonist Inhalers
  - Statins
- 11. General Announcements** **8:20– 8:30**  
**Selected FDA Safety Alerts**
- Fungal Meningitis Outbreak Originating from Compounding Pharmacy
  - Pramipexole: Possible Risk of Heart Failure
- 12. Adjourn** **8:30**